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Abstract 
Background: To investigate whether the Helicobacter pylori (H. pylori) status 
influences levels of antibodies against mycobacterial heat shock protein (hsp) 
65 and human hsp60 in systemic autoimmune diseases and studied the 
concentration of anti-H. pylori antibodies in autoimmune patients and healthy 
controls. 
Materials and Methods: Antibodies against human heat-shock protein hsp60, 
mycobacterial heat-shock protein hsp65 were analyzed by ELISA. Anti-
Helicobacter antibodies were determined by enzyme immunoassay. 
Results: There was markedly higher prevalence of H. pylori infection in 
undifferentiated connective tissue disease (82%) (n = 33) and systemic 
sclerosis (78%) (n = 55) but not in systemic lupus erythematosus (n = 49), 
polymyositis/dermatomyositis (n = 14), rheumatoid arthritis (n = 21) or primary 
Raynaud’s syndrome (n = 26) compared to controls (59%) (n = 349). In 
autoimmune diseases H. pylori infection was associated with elevated levels of 
anti-hsp65 (p = 0.008) but not of anti-hsp60. Anti-hsp65 levels were significantly 
higher in H. pylori-infected (n = 129) than in uninfected patients (n = 69) (p = 
0.0007). 
Conclusions: These findings indicate that in autoimmune diseases the infection 
with the H. pylori bacterium is associated with increased concentration of anti-
mycobacterial hsp65. 
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Introduction 
 
Helicobacter pylori (H. pylori) is a Gram-negative organism that colonizes the 
acid-secreting portion of the stomach. It always causes inflammatory 
histological lesions, which predispose to gastro-duodenal peptic disease, 
gastric cancer and lymphoma [1, 2, 3]. 
 
Several studies have been published on the issue of H. pylori and 
autoimmunity, and almost all of them seemed to give credit to H. pylori for 
influencing the occurrence or course of some autoimmune diseases. In 
idiopathic thrombocytopenic purpura successful eradication of H. pylori resulted 
in a significant decrease of anti-platelet antibody titers and increase of platelet 
count [4]. Conversely, no significant differences were found in patients who 
were treated but not cured. Cross-mimicry mechanisms have been suggested 
to explain this phenomenon [4]. In rheumatoid arthritis the eradication of H. 
pylori infection led to a significant improvement of all indices of disease activity. 
No significant changes were observed in controls [5]. In one study about 80% of 
patients with primary Sjögren’s syndrome (SjS) had antibodies against H. pylori 
[6]. The prevalence was significantly higher than that found in various 
autoimmune diseases and healthy persons. Increased seroprevalence of H. 
pylori in systemic sclerosis (SSc) has been reported by several groups [7, 8, 9, 
10]. Some studies indicated association between H. pylori infection and 
Raynaud’s syndrome, speculating that increased levels of cytokines and acute 
phase reactants, C-reactive protein, and fibrinogen cause vasospasm and 
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platelet aggregation [11, 12]. By contrast, no increased titers of anti-H. pylori 
antibodies were found in the sera from patients with systemic lupus 
erythematosus (SLE), rheumatoid arthritis (RA) and polymyositis/ 
dermatomyositis (PM/DM) [6]. 
 
H. pylori sheds extracellular products that elicit local and systemic immune 
responses that could be responsible for tissue damage [2, 13, 14]. Among 
these, a 60 kDa protein, belonging to the heat-shock proteins (hsp) seems to 
play an important role. Since microbial hsp have a high level sequence 
homology with their mammalian counterparts, and some antigenic determinants 
may be present in both agent and host proteins, it has been postulated that 
immune response to H. pylori hsp could be involved in the pathogenesis of 
systemic and organ specific autoimmune diseases [2, 15, 16, 17]. 
 
Previously we have reported on the measurement of antibodies against human 
hsp60 and mycobacterial hsp65 in various autoimmune diseases (SLE, 
undifferentiated connective tissue disease [UCTD], primary Raynaud’s 
syndrome, [PRS], RA, PM/DM), and healthy blood donors. No significant 
differences in the anti-hsp60 and anti-hsp65 antibody levels were found 
between any patient group and the controls except significantly higher anti-hsp 
concentrations in UCTD (anti-hsp60: p = 0.0094, anti-hsp65: p = 0.0108, 
respectively) [18]. According to several reports serum levels of antibodies 
against the hsp60 of H. pylori are higher in the H. pylori-infected than in the 
uninfected subjects [2, 19, 20]. In addition, titers of these antibodies were 
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reduced after H. pylori eradication [21]. Therefore we measured anti-H. pylori 
antibodies in the sera tested previously by us for anti-hsp antibodies of patients 
with autoimmune diseases, and assessed whether the H. pylori status 
influences the levels of antibodies to mycobacterial hsp65 and human anti-
hsp60. Another purpose of the present work was to systematically measure of 
H. pylori antibodies in a high number of patients with different systemic 
autoimmune diseases and healthy controls. 
 
 
Methods 
 
Patients 
All patients of these groups were cared at the 2nd Department of Internal 
Medicine, University Medical School, Pécs, Hungary. Forty-nine patients with 
SLE (10 males, 39 females, age: 41.7  15.4 years, mean ± SD), 14 patients 
with PM/DM (2 males, 12 females, 48.1  12.7 years), 21 patients with RA (6 
males, 15 females, 46.0  17.6 years), 55 patients with SSc (6 males, 49 
females, 49.9  12.1 years), 33 female patients with UCTD (42.5  11.7 years) 
and 26 patients with PRS (6 males, 20 females, 39.4  10.6) were included in 
the study. All cases fulfilled the accepted international criteria (A-E) [22, 23, 24, 
25, 26, 27, 28, 29]. The study was approved by the local Ethical Committee of 
the 2nd Department of Internal Medicine. 
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Healthy controls 
Two groups of healthy blood donors served as controls for the present study. 
The first group tested for both anti-H. pylori and anti-hsp antibodies consisted of 
192 healthy blood donors (111 males, 81 females, 47.1  9.8 years old). Serum 
samples from 157 other blood donors (117 males, 40 females, 44.4 ± 9.7 years 
old) were tested only for anti-H. pylori antibodies. 
 
Analysis of antibodies to heat-shock proteins 
The levels of IgG-type antibodies reacting with proteins of the chaperonin 60 
family (recombinant human hsp60, StressGen, SPP-740, Victoria, Canada; 
recombinant M. bovis hsp65 [batch MA14, GBF, Braunschweig, Germany, 
supported by the UNDP/World Bank/WHO Special Program for Research and 
Training in Tropical Diseases]) was assessed by ELISA. ELISA plates were 
coated with 0.1 g/well human hsp60 or M. bovis hsp65. After washing and 
blocking (PBS, 0.5 % gelatin) the wells were incubated with 100 l of serum 
samples diluted 1:500 in PBS containing 0.5% gelatin and 0.05% Tween 20. 
Binding of anti-hsp antibodies was determined using -chain specific anti-
human IgG peroxidase labelled antibodies (Sigma, St. Louis, USA) and o-
phenylene-diamine (Sigma) detection system. The optical density was 
measured at 490 nm (reference at 620 nm) and the means of duplicate wells 
were calculated [30]. A serial dilution of a control anti-hsp60 rabbit polyclonal 
antiserum (StressGen, SPA-804, reacting with all hsp tested) was used as 
standard. Data obtained as optical density values were calculated to arbitrary 
unit/ml values related to this standard. 
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Measurement of the IgG antibodies against Helicobacter pylori 
Titer of anti-H. pylori antibodies was determined by the recomWell Helicobacter 
IgG test (Mikrogen GmbH, Martinsried, Germany). In this indirect ELISA test 
recombinant H. pylori antigens bound to the solid phase were incubated with 10 
l of serum samples (1:101 dilution) at 37 C for 1 hour. After washing the 
plates were then incubated with peroxidase-conjugated anti-human IgG 
antibodies at 37 C for 30 minutes followed by washing. The antibody titer was 
detected by a color reaction using TMB solution at room temperature for 30 
minutes, stopped by phosphoric acid. The optical density was measured at 450 
nm. The results were expressed as an index value. The cut-off value was 
based on the study of a large control group. A positive control (= calibrator) in 
combination with a Factor value was used to determine the OD of cut-off. The 
value of the Factor was given in the control certificate included with each kit. 
The OD cut-off in our laboratory was 1.0. Subjects with a H. pylori antibody 
concentration equal to or below this value were considered as not infected 
whereas subjects with concentration exceeding cut-off were considered to be 
infected with the bacterium. 
 
Statistical analysis 
Data were analyzed with GraphPad Prism version 3.0 for Windows (GraphPad 
Software, San Diego California USA). As the values of antibody to heat-shock 
proteins and H. pylori index values were not normally distributed, non-
parametric tests and post hoc tests were used for group comparisons. 
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Categorical variables were compared with the 2 and Fisher’s exact tests. 
Multiple regression analysis was performed by the SPSS program, version 10.0 
(SPSS Inc., Chicago, Ill, USA). 
 
Results 
 
Antibodies against H. pylori in the sera of patients with different autoimmune 
diseases and healthy persons 
Anti-H. pylori antibody levels were determined in the sera of both groups of 
healthy blood donors (altogether 349 subjects) and in 198 patients with different 
autoimmune diseases (UCTD, SSc, SLE, PRS, RA, and PM/DM). Antibody 
levels to H. pylori were significantly (p < 0.0001) higher in the group of patients 
with autoimmune diseases (median [interquartile range] of the index: 2.4 [0.7-
5.4]) as compared to control subjects (1.4 [0.5-3.0]. Since the proportion of 
females to males was markedly higher in the latter group (174 to 24 as 
compared to 121 to 227 among the healthy subjects) we compared the 
antibody levels to H. pylori by using multiple regression analysis adjusted to age 
and gender of the subjects tested. Patients had significantly (p = 0.014) higher 
H. pylori indices than the controls even after adjustment to age and gender. 
 
The difference between healthy subjects and patients with autoimmune 
diseases was due to the significantly higher prevalence of H. pylori infection in 
two diseases: UCTD (82%) and SSc (78%) compared with healthy controls 
(59%) (Table 1). The median value of the H. pylori index was significantly 
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higher in these two diseases than in the healthy controls as demonstrated by 
ANOVA completed with a post hoc test. By contrast, H. pylori infection did not 
occur significantly more frequently and H. pylori index was not significantly 
higher in SLE, PRS, RA or PM/DM patients than in the healthy subjects (Table 
1). 
 
Relationship between anti-H. pylori antibodies and anti-60 kD heat shock 
protein antibodies in the sera of patients with autoimmune diseases 
In the whole group of 198 patients with different autoimmune diseases the 
serum concentration (index) of anti-H. pylori antibodies exhibited a highly 
significant positive correlation with antibodies against M. bovis hsp65 (r = 0.335, 
p < 0.0001) whereas no correlation with serum levels of antibodies against 
human hsp60 was found (r = 0.056, p = 0.441). By contrast, in the sera of 
healthy controls there was a weak but highly significant positive correlation 
between the levels of anti-hsp60 and anti-H. pylori antibodies (data not shown). 
 
When patients and controls were divided into two groups (those with a H. pylori 
index equal to or exceeding 1.0 (considered infected with the bacterium) and 
those with a H. pylori index <1.0 considered to be not infected) marked 
differences were found in the levels of antibodies to mycobacterial hsp65 
(Table 2). The levels of these antibodies were significantly (p = 0.0007) lower in 
the sera of the 69 not infected patients than in those from the 129 H. pylori-
infected patients whereas no difference in the anti-hsp65 antibody 
concentration was found between infected and not infected healthy controls 
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(Table 2). By contrast, median serum concentration of anti-hsp60 antibodies did 
not differ between H. pylori-infected and not infected patients whereas a slight 
but significant difference was observed in the group of healthy controls (Table 
2). 
 
Significant differences between the patients and controls were found only In the 
H. pylori positive group: anti-hsp65 levels were almost 1.5 times higher in the 
patients than in the controls (p = 0.008) whereas in the H. pylori negative group 
anti-hsp65 antibody concentration was about the same in the healthy subjects 
and the patients.  No differences in the anti-hsp60 antibody levels were found 
between patients and controls in either group (Table 2). 
 
By using ANOVA, we did not find significant differences among groups with 
different autoimmune diseases either in the levels of anti-hsp60 or anti-hsp65 
antibodies (data not shown). 
 
Discussions 
We have studied two questions: i) is there any difference in the frequency of H. 
pylori infection between patients with different autoimmune diseases and 
healthy persons, and ii) does infection with H. pylori influence the occurrence of 
antibodies against human and mycobacterial hsp in the same patients and 
healthy subjects? 
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As for the frequency of H. pylori infection, patients with autoimmune diseases 
as a whole had significantly higher average IgG anti-H. pylori levels than 
healthy controls. This difference, however, could be solely due to an increased 
serum concentration in UCTD and SSc. More importantly, the frequency of high 
(> 1.0) anti-H. pylori indices, (considered as the sign of infection), was higher 
than those in the healthy control group only in these two diseases. In 
accordance with previous results the patients with SLE, PRS, RA and PM/DM 
did not differ from the healthy group in this respect either [9]. Thus our present 
findings indicate that the frequency of H. pylori-infected subjects exceed that in 
the healthy normal population only in some autoimmune diseases. 
 
Of particular relevance is the preferential occurrence of H. pylori infection in 
UCTD that refers to diseases in evolution toward particular differentiated 
particular connective tissue disorders including SSc. To our best knowledge, no 
data on the frequency of anti-H. pylori antibodies in this disease have been 
published yet. Further studies are needed to evaluate the possible diagnostic 
and prognostic significance of H. pylori infection in such cases. In accordance 
with our results several recent findings indicate increased rate of H. pylori 
infection in patients with SSc [7, 8, 9, 10]. The preferential occurrence of H. 
pylori infection in SSc may be explained in two ways. First, an increased 
prevalence of H. pylori infection might be favored by the disturbed 
gastrointestinal motility, a clinical phenomenon well known in patients with SSc. 
The second explanation may be that H. pylori infection and the immunological 
mechanisms operative in the course of SSc may be related. 
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H. pylori-associated hsp60, human hsp60 and mycobacterial hsp65 are 
members of the 60-kD family of heat shock proteins, they are believed to share 
high sequence homology. Thus potential exists for cross-reaction of antibodies 
directed against these proteins [16, 20, 31, 32, 33, 34]. Several recent 
observations indicate that the titer of antibodies against H. pylori hsp60 is 
significantly higher in H. pylori-infected than in the not infected subjects [2, 19, 
20]. Furthermore, the titration of these antibodies can be used for early 
serological monitoring of H. pylori eradication treatment [21]. Only scarce data 
are, however, available on the influence of H. pylori infection on serum 
concentration of antibodies against other members of the 60 kD hsp family [31, 
35]. To our best knowledge no such study has been performed in patients with 
autoimmune diseases. 
 
By using sensitive ELISA methods that were found to be suitable to measure 
the serum concentrations and study the properties of antibodies against 
different members of 60 kD hsp [30, 36, 37] we obtained only weak differences 
between H. pylori-infected and not infected healthy individuals in the levels of 
anti-human hsp60 and anti-mycobacterial hsp65 IgG antibodies [18]. No 
influence of H. pylori infection on the serum concentration of these antibodies 
has been found previously whereas IgA type antibodies to hsp60 and hsp65 
were elevated in patients with atrophy compared to H. pylori negative controls 
[35]. Sharma et al - in accordance with our present findings - found IgG 
antibodies recognizing human hsp60 that could be detected by immunoblotting 
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in H. pylori-infected persons but found no difference between H. pylori-infected 
and not infected individuals in antibodies to M. bovis hsp65 [31]. 
 
The normal level of anti-hsp60 antibodies in patients with autoimmune diseases 
supports our recent hypothesis on the regulation of the autoantibodies against 
human hsp60 [36]. According to this hypothesis anti-hsp60 antibodies can be 
considered as bona fide natural autoantibodies. Our unpublished observations 
indicate that the level of these antibodies is constant for years and even 
decades as that of other natural autoantibodies [38, 39]. If this assumption is 
true, polyclonal B cell activation, characteristic for some autoimmune disease, 
such as SLE is expected to have no influence on their serum concentration. 
Our present findings are compatible with this assumption as is our previous 
observation on the normal anti-hsp60 antibody levels in HIV-infection, a disease 
that is also associated with polyclonal B cell activation [40]. 
 
In contrast to anti-hsp60, serum concentration of antibodies against 
mycobacterial hsp65 correlated to that of anti-H. pylori antibodies in patients 
with autoimmune diseases. Moreover, in these diseases anti-hsp65 antibodies 
were found in significantly higher titers in H. pylori-infected than in not infected 
patients. Human hsp60 and mycobacterial hsp65 share several common 
epitopes therefore anti-hsp60 and anti-hsp65 antibodies cross-react with each 
other. However, the overlap between the two proteins is only partial, they have 
different epitope specificities and complement activating abilities [30]. Since 
anti-mycobacterial hsp65 represents antibody against bacterial hsp combined 
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infection with H. pylori and some other bacteria might contribute to the 
observed results. 
 
There are marked differences in the epitope specificity between the H. pylori 
associated hsp60, other bacterial 60 kD hsps and human hsp60 as well. The 
amino acid sequences of two regions (residues 181 to 204 and 204 to 229) on 
H. pylori hsp60 were different from the amino acid sequences of other bacterial 
hsp60s, whereas the amino acid region of residues 189 to 203 on H. pylori 
hsp60 is conserved among several bacterial hsp60s and human hsp60 [21]. 
Our present findings indicate that a part of the antibodies reacting with 
mycobacterial hsp65 represent antibodies against cross-reactive epitopes 
between mycobacterial hsp65 and H.pylori-associated hsp60 and their elevated 
titer in H. pylori-infected patients reflects high serum concentration of antibodies 
against H. pylori hsp60 [2, 19, 20]. Increased formation of these antibodies in 
H. pylori-infected patients with some autoimmune diseases may be a part of the 
immune dysregulation characteristic for the given disease. More studies are 
needed for a better understanding of the development and the possible 
pathological significance of anti-hsp antibodies with a large array of specificity 
in autoimmune diseases. 
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Table 1 
Association of different autoimmune diseases and infection with Helicobacter 
pylori 
 
Patients with Number of 
subjects 
tested/infected 
(H. pylori 
prevalence %)+ 
H. pylori index, median 
(interquartile range) 
Healthy controls 349/206 (59%) 1.50 (0.50-3.95) 
Undifferentiated connective tissue 
disease (UCTD)  
33/27 (82%)* 3.40 (1.10-6.00)* 
Systemic sclerosis (SSc) 55/43 (78%)** 3.50 (1.40-5.65)** 
Systemic lupus erythematosus (SLE) 49/28 (57%) 1.50 (0.60-4.40) 
Primary Raynaud’s syndrome (PRS) 26/12 (46%) 2.25 (0.60-5.35) 
Rheumatoid arthritis (RA) 21/11 (52%) 1.65 (0.60-4.75) 
Polymyositis/dermatomyositis 
(PM/DM) 
14/11 (79%) 2.10 (0.50-4.35) 
p value 0.0049 (2 test) 0.0029 (Kruskal-Wallis test) 
+H. pylori index > 1, *p<0.05, **p<0.01, Fisher’s exact test and Dunn post hoc 
test for the column 1 and 2, respectively 
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Table 2 
Comparison of the serum concentration of the antibodies to mycobacterial 
hsp65 and human hsp60 in patients with autoimmune diseases and healthy 
subjects infected or not infected with Helicobacter pylori 
 
 Anti-hsp60, median (interquartile 
range) (number of subjects) 
Anti-hsp65, median (interquartile 
range) (number of subjects) 
 Healthy 
subjects 
Patients with 
autoimmune 
diseases 
P 
value* 
Healthy 
subjects 
Patients with 
autoimmune 
diseases 
P value* 
H 
pylori 
index < 
1.0 
87.7 (50.2-
140.5) (79) 
93.1 (64.7-
164.9) 
(69) 
0.340 9.8 (4.6-
21.5) (79) 
10.4 (4.7-
17.0) 
(69) 
0.949 
H 
pylori 
index > 
1.0 
116.3 (71.1-
179.4) (113) 
119.2 (72.3-
202.5) 
(129) 
0.533 11.3 (4.9-
24.2) 
(113) 
15.8 (8.4-
31.3) (129) 
(129) 
0.008 
P value 0.024 0.182 - 0.473 0.0007 - 
Total 100.8 (64.4-
170.9) (192) 
110.6 (66.3-
199.6) (198) 
0.187 10.7 (4.9-
21.7) 
(192) 
12.7 (7.2-
25.5) (198) 
0.023 
 
